FDA Sets New Electronic Filing Standards for Drug Approval Paperwork
Published Date: 10/16/2026
Notice
Summary
Starting January 16, 2027, the FDA will reject drug and biologic electronic submissions that don’t meet the new eCTD data standards (versions 3.2.2 and 4.0). This affects companies sending electronic documents for drug and biologic approvals, pushing them to update their files to avoid costly delays. The FDA also welcomes comments anytime, making this a key moment to get ready and stay compliant!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA will reject non‑compliant eCTD submissions
Starting January 16, 2027, the FDA will reject electronic drug and biologic submissions that fail the new high‑severity eCTD validations. The affected validations include eCTD v3.2.2 validations numbered 2024 and 2025 and eCTD v4.0 validations eCTD4-084, eCTD4-085, US-eCTD4-561, US-eCTD4-562, US-eCTD4-563, and US-eCTD4-564. If your submission is subject to 21 U.S.C. 379k-1(a), it must be submitted in the eCTD format and meet the currently supported eCTD validations or be exempt or waived.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21194, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Antarctic Marine Living Resources Conservation and Management Measures
NOAA is asking for approval to keep collecting info from 79 folks involved in Antarctic marine research and fishing. They want to make sure everyone follows rules to protect sea life, with tasks like applying for permits and reporting catches. This keeps the ocean safe without adding extra hassle or costs, and you’ve got 30 days to share your thoughts!
Next: 2026-21196, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Alaska Region Amendment 80 Program
NOAA is asking to keep collecting info from 7 fishing businesses in Alaska to manage the Amendment 80 Program, which controls fishing rules in the Bering Sea and Aleutian Islands. This update extends the current paperwork, which takes about 14 hours total each year, with no new fees or big changes. They’re giving the public 30 more days to share thoughts before final approval.